- Credit Suisse has raised the price target on Kura Oncology Inc KURA to $29 from $27.
- The analysts say that evidence of an effective and tolerable agent and a clear recommended phase 2 dose for ziftomenib should support an upside of ~$8-10/share to their NPV. A topline update from Phase 1b study is expected in Q3 and detailed data in Q4.
- Downside scenarios include an incomplete/inconclusive update that may disappoint expectations, though the scenario is unlikely.
- Fully de-risked, Credit Suisse believes the relapsed or refractory setting might be worth ~$18/share, with expansion into the frontline setting taking the total asset value to ~$40-45/share.
- The analysts view ziftomenib as best-in-class potential among the menin inhibitors, as it may differentiate on tolerability/safety and allow for a more comprehensive combo strategy.
- With initial approval in 2025, peak sales can potentially be over $1 billion, assuming successful frontline expansion.
- Kura's management has consistently said that a 20-30% CR/CRh rate with mDOR 4-6 months would likely be an approvable profile, consistent with the company's survey/KOLs.
- Price Action: KURA shares are up 6.15% at $19.04 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorBiotechNewsHealth CarePrice TargetSmall CapAnalyst RatingsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in